NEW
PREVENTIVE USE

Eso-SPONGE®
ENDOLUMINAL VACUUM THERAPY FOR THE TREATMENT AND PREVENTION OF ANASTOMOSIS INSUFFICIENCY AND PERFORATIONS IN THE UPPER GI TRACT
Anastomotic leakages or other defects in the upper gastrointestinal tract can have serious consequences for the affected patients. Different parameters, like the size, location, time to diagnosis of the lesion, but also the general condition of the patient, have a significant influence on the clinical outcome of the patient. Often this situation is accompanied by symptoms of sepsis and a significant morbidity rate with corresponding substantial mortality rate. For this reason the treatment of this clinical situation is often a challenge for the clinician.

Besides surgical examination and the endoscopic stent system, good experiences have been obtained with the Endo-SPONGE® therapy for the lower gastrointestinal tract. Now also the endoluminal vacuum therapy for the upper gastrointestinal is available – Eso-SPONGE®.
ANASTOMOTIC LEAKAGE IS A SEVERE COMPLICATION FOLLOWING GASTRIC AND ESOPHAGEAL SURGERY

Anastomotic leakage (AL):
- Is associated with high morbidity and mortality.1-10
- Can occur after oesophageal surgery in up to 30% of cases.1-10
- Can occur after gastric bypass and sleeve gastrectomy surgery in 1.5% and 4.9%.1-10
- Has higher leak rate in cervical anastomosis (12.3% - 13.6%) than in thoracic anastomosis (2.9% - 9.3%).11, 12
- Increases hospital costs.1-10
- Increases length of stay.13
- Increases the reoperation risk.13
- Increases the risk of cancer recurrence.14
- Is related to worse long-term survival.13
- Increases the risk of stricture formation.13
- Delays oral feeding.13

ANASTOMOTIC LEAKAGE (AL) DIRECTLY AFFECTS THE MORTALITY RATE

- Mortality in patient with AL is reported to be between 2% - 35%.13, 15, 16
- AL increases the mortality rate compared to no leakage.15
- Mortality is increased 2x in delayed AL diagnostic & treatment > 24h.16
Eso-SPONGE®
ENDOLUMINAL VACUUM THERAPY FOR THE TREATMENT OF ANASTOMOSIS INSUFFICIENCY AND PERFORATIONS IN THE UPPER GI TRACT
SUGGESTED BENEFITS OF VACUUM THERAPY ON THE TISSUE

- Increase blood flow and edema reduction.\(^{17}\)
- Granulation tissue formation and extracellular synthesis.\(^{17}\)
- Decrease of bacterial contamination and secretion.\(^{18}\)

VACUUM THERAPY FOR THE UPPER GI

- Endoluminal Vacuum Therapy (EVT) is a feasible, safe and high efficient approach to treat anastomotic leaks and perforations within the upper GI.\(^{8-10, 19-38}\)
- EVT is used as the first method of choice for oesophageal leaks or perforations already in several hospitals.\(^{8, 10, 19-35}\)
- EVT has the potential to become the new standard of care for this indication.\(^{8, 10, 19-35}\)

Eso-SPONGE\(^{\circ}\) TREATMENT SUGGESTED BENEFITS

- The mean treatment duration time reported is less than 30 days.\(^{8, 9, 20, 24, 28, 29, 36-39}\)
- The average rate of successful treatment with Eso-SPONGE has been reported to occur in 84% of patients.\(^*\)\(^{8, 9, 10, 24, 28, 29, 36-39}\)
- Early treatment is likely to achieve faster healing, shorter duration of treatment & hospital stay and less complications.\(^{5, 8-10, 24, 26, 30, 36-40}\)
- Continuous drainage, no secretion accumulation.\(^{8-10, 24, 28, 29, 36-38, 41-43}\)
- Infection control.\(^{8-10, 24, 28, 29, 36-38, 41-43}\)
- Debridement, quick cleaning of the wound cavity.\(^{8-10, 24, 28, 29, 36-38, 41-43}\)
- Promotion of granulation tissue ingrowth.\(^{8-10, 24, 28, 29, 36-38, 41-43}\)
- Mechanical reduction of the wound cavity.\(^{8-10, 24, 28, 29, 36-38, 41-43}\)
- Can be combined with enteral feeding.\(^{8, 24, 28, 36, 37, 39}\)
- If necessary, Eso-SPONGE can be combined with stent placement or operative revision for better control of the septic focus.\(^{8-10, 24, 44, 28, 29, 37, 38, 45}\)
- Contribute significantly to the reduction of morbidity and mortality of the patients.\(^{5-10, 19-37, 38, 41}\)
- Well tolerated with good short- and long-term clinical outcomes.\(^{8-10, 19-37, 38, 41}\)
- Likely to be superior to stent treatment and reduced need for surgical revision, and with less strictures.\(^{1, 10, 22, 23, 27-30}\)

* According to the product-related literature covered herein, wound closure or repair was achieved principally by Eso-SPONGE\(^{\circ}\), though some patients in some studies required additional stent therapy or surgical revision to ensure complete closure repair.
Eso-SPONGE®

ENDOLUMINAL VACUUM THERAPY FOR THE TREATMENT OF ANASTOMOSIS INSUFFICIENCY AND PERFORATIONS IN THE UPPER GI TRACT

THERAPY PROCEDURE

STEP 1

STEP 2

STEP 3

STEP 4

STEP 5

STEP 6

STEP 7

STEP 8

STEP 9

A

B

a)  
b)
TREATMENT CRITERIA

Eso-SPONGE® THERAPY PRINCIPLE

Treatment of anastomotic leaks or perforations in the upper gastrointestinal tract* by means of negative pressure including intraluminal or intracavitary therapy of paraoesophageal and mediastinal septic focus or localised abscesses endoscopically accessible.

*For use in the upper gastrointestinal tract understood as esophagus, stomach and duodenum, and endoscopically accessible within the range of the overtube length.

Eso-SPONGE® TREATMENT

Intraluminal and intracavitary therapy possible, see below instructions for intracavitary positioning of the Eso-SPONGE®.

STEP 1: The wound cavity should be measured (length and diameter) with an appropriate endoscope (leave the overtube at the distal part of the endoscope to be used in the next step). Cut the sponge slightly smaller than the cavity.

STEP 2: Push the overtube over the endoscope and introduce it under visual control using the endoscope as a guide until the tapered end is near the end of the cavity, leaving enough space for the sponge to deploy.

STEP 3: After leaving the overtube in the required position, place the drain of the sponge through the overtube. Place it into the pusher and introduce the sponge, previously impregnated with sterile hydrogel based on glycerol, through the overtube.

STEP 4: Push the Eso-SPONGE® to the mark with the pusher. The sponge is now at the end of the overtube (uncut sponge).

STEP 5: Advance gently until the sponge is expelled from the overtube, the resistance will fade once the sponge is released. Withdraw the overtube and pusher together.

STEP 6: The sponge will now expand in the leakage cavity. Check the position of the sponge using the endoscope to make sure that the sponge has not migrated and apply appropriate correction by means of endoscopic grasping forceps if necessary.

STEP 7: Transnasal channelling: Feed a 16 CH gastric tube in through the nose and out through the mouth. Cut off the atraumatic tip.

STEP 8: Connect the drain to the gastric tube in front of the mouth. Pull the stomach tube together with the drain back through the nose.

STEP 9: Disconnect the gastric tube. The drain is now transnasally channelled.*

* Remove of the sponge only through the mouth and never through the nose (!)

CONNECTION TO THE VACUUM SOURCE

How to use the variable speed medical vacuum pump MV 1 (MTG Sulzbach, Germany – distributed by B. Braun):

Fig. A:

a) The redon drain must be introduced in the Y-connector to the minimum depth marked by dashed line.
b) The connection of the secretion bottle must be introduced in the Y connector to the minimum depth marked by dashed line.

Fig. B: Connect the filter using a Luer Lock to the pump. Then attach the cylinder hose from the secretion bottle to the filter.

Suction is applied, if possible, under endoscopic inspection of the sponge at a negative pressure of 50 to 125 mmHg. Regular checking of the system is mandatory. The system must be changed every 48 - 72 hours and, where appropriate, a new sponge inserted.

For more information look at the instructions for use.
Eso-SPONGE®

ENDOLUMINAL VACUUM THERAPY FOR THE TREATMENT OF ANASTOMOSIS INSUFFICIENCY AND PERFORATIONS IN THE UPPER GI TRACT

MV1 VACUUM PUMP
- Pre-set at 125 mmHg
- Patient mobility thanks to battery
- Closed system
- 1000 ml filling volume
- Alarm system
LITERATURE SUMMARY ON THE USE OF VACUUM THERAPY TO TREAT ANASTOMOSIS INSUFFICIENCY AND PERFORATIONS IN THE UPPER GI TRACT

<table>
<thead>
<tr>
<th>YEAR</th>
<th>PAPER REFERENCE</th>
<th>N</th>
<th>INDICATION</th>
<th>TREATMENT DURATION (DAYS)</th>
<th>NUMBER OF SPONGE CHANGES</th>
<th>RATE OF HEALING</th>
<th>TYPE OF DEFECT (N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>Bludau et al.28</td>
<td>77</td>
<td>Esophageal perforations and leaks from esophagogastrostomies</td>
<td>11 (1 – 65)</td>
<td>2.75 (1-9)</td>
<td>77.90 %</td>
<td>59 18 0</td>
</tr>
<tr>
<td>2016</td>
<td>Kuehn et al.8</td>
<td>21</td>
<td>Esophageal and gastric resections, esophageal perforation</td>
<td>15 (3-46)</td>
<td>5 (1-14)</td>
<td>90.5 %</td>
<td>11 8 2</td>
</tr>
<tr>
<td>2020</td>
<td>Jung et al.48</td>
<td>30</td>
<td>Esophageal anastomotic leaks and perforations</td>
<td>16.1 (2–58)</td>
<td>AL = 3.6 (1-13) IP = 5.1 (1-12)</td>
<td>83.3 %</td>
<td>23 7 0</td>
</tr>
</tbody>
</table>

AL: anastomotic leak, IP: iatrogenic perforation, O: other

RECOMMENDED PLACEMENT OF THE SPONGE

- Place the sponge preferentially in the cavity created by the leak or perforation: **Intracavitary positioning**.
- When intracavitary placement is challenging or not possible it is an option to place the sponge in the lumen in front of the defect: **Intraluminal positioning**.18, 34

![A Intracavitary positioning](image1)

![B Intraluminal positioning](image2)
Eso-SPONGE®
ENDOLUMINAL VACUUM THERAPY FOR THE TREATMENT OF ANASTOMOSIS INSUFFICIENCY AND PERFORATIONS IN THE UPPER GI TRACT

PRODUCT AND ORDERING INFORMATION

Eso-SPONGE®
- Overtube (2 sizes available)
- Pusher
- Irrigation set
- Y-shaped connector
- Slide clamp

NOT INCLUDED IN THE SET:
- Sterile hydrogel (glycerol based)
- Gastric tube CH 16
- Variable speed medical vacuum pump (see information about MV1 pump in this brochure)
This therapy requires the use of a standard or therapeutic gastroscope.

<table>
<thead>
<tr>
<th>ART.-NO.</th>
<th>NAME</th>
<th>DIAMETER OVERTUBE</th>
<th>CONTENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>5526550</td>
<td>Eso-SPONGE® 13 mm</td>
<td>Inner: 13 mm Outer: 17 mm</td>
<td>1 intervention set</td>
</tr>
<tr>
<td>5526540</td>
<td>Eso-SPONGE® 15 mm</td>
<td>Inner: 15 mm Outer: 19 mm</td>
<td>1 intervention set</td>
</tr>
</tbody>
</table>

Vacuum source (MV1, MTG Sulzbach)

<table>
<thead>
<tr>
<th>ART.-NO.</th>
<th>NAME</th>
<th>CONTENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTG19116</td>
<td>MV1</td>
<td>1x Low vacuum pump</td>
</tr>
<tr>
<td>MTG18022</td>
<td>Bacterial filter</td>
<td>20 units</td>
</tr>
<tr>
<td>MTG18032</td>
<td>Collecting bottle</td>
<td>15 units</td>
</tr>
</tbody>
</table>
Eso-SPONGE®

NEW INDICATION: PREVENTIVE THERAPY TO REDUCE THE RISK OF ANASTOMOTIC LEAKS IN THE Upper GI TRACT

NEW PREVENTIVE USE

12.3% - 13.6%
LEAKAGE RATE IN CERVICAL ANASTOMOSIS 11, 12

2.9% - 9.3%
LEAKAGE RATE IN THORACIC ANASTOMOSIS 11, 12

1ST CHOICE IS ALWAYS PREVENTION!

Some patients have higher risk of developing an anastomotic leakage after esophagectomy due existing conditions such as:
- Calcification or arteries 46
- Heart failure, hypertension, renal insufficiency 11
- Obesity 47
- Diabetes 11

Now it is possible to use Eso-SPONGE® to reduce the risk of anastomotic leakages.
PILOT STUDY FOR PREEMPTIVE USE OF Eso-SPONGE®

Preemptive endoluminal vacuum therapy to reduce anastomotic leakage after esophagectomy: a game-changing approach?

Dis Esophagus. 2019 Jul 1;32(7)

Authors
C Gubler 1, D Vetter 2, H M Schmidt 2, P C Müller 2, B Morell 1, D Raptis 3, C A Gutschow 2

Affiliations
1 Department of Gastroenterology, and Transplant Surgery, University Hospital Zurich, Zurich, Switzerland.
2 Department of Visceral and Transplant Surgery, University Hospital Zurich, Zurich, Switzerland.
3 Department of HPB Surgery and Liver Transplantation, Royal Free London NHS Foundation Trust, London, United Kingdom.

Abstract
Endoluminal vacuum therapy (EVT) is an accepted treatment for anastomotic leakage (AL) after esophagectomy. A novel concept is to use this technology in a preemptive setting, with the aim to reduce the AL rate and postoperative morbidity. Preemptive EVT (pEVT) was performed intraoperatively in 19 consecutive patients undergoing minimally invasive esophagectomy, immediately after completion of esophagogastrectomy. Twelve patients (63%) were high-risk cases with severe comorbidity. The EVT device was removed routinely three to six (median 5) days after esophagectomy. The endpoints of this study were AL rate and postoperative morbidity. There were 20 anastomoses at risk in 19 patients. One patient (5.3%) experienced major morbidity (Clavien-Dindo grade IIIb) unrelated to anastomotic healing. He underwent open reanastomosis at postoperative day 12 with pEVT for redundancy of the gastric tube and failure of transition to oral diet. Mortality after 30 days was 0% and anastomotic healing was uneventful in 19/20 anastomoses (95%). One minor contained AL healed after a second course of EVT. Except early proximal dislodgement in one patient, there were no adverse events attributable to pEVT. The median comprehensive complication index 30 days after surgery was 20.9 (IQR 0-26.2). PEVT appears to be a safe procedure that may have the potential to improve surgical outcome in patients undergoing esophagectomy.

Keywords: anastomotic leakage; complications; minimally invasive esophagectomy; outcome research.

©The Author(s) 2018. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus.

PREVENTIVE USE OF Eso-SPONGE®

Follow the insertion system as described for the treatment in steps 1 to 6 placing the end of the overtube at the anastomosis site.

Release the Eso-SPONGE®, so that the sponge must be positioned at the anastomosis site.

The drainage can be positioned transnasally (see steps 7 to 9).

Connect the device to the vacuum source, low vacuum pump from MTG.

Apply a continuous negative pressure of 75 mmHg as previously described.

Leave the sponge for 4 to 6 days and retire the sponge.

RESULTS OF THE PILOT STUDY FOR PREEMPTIVE USE OF Eso-SPONGE®

- n=20 patients
- 19 patients recovered with no leakage.
- 1/20 leakage
- 1 patient develop a non symptomatic leak which was resolved with a second round of vacuum therapy.
- 20 patients had a sponge post surgery at the anastomotic site for 4-6 days.
REFERENCES


4. Schaheen L, Blackmon SH, Nason KS. Optimal approach to the management of esophageal perforations: systematic review. Dis Esopha-.


AESCULAP® – a B. Braun brand

Manufacturer
Endo-SPONGE, Eso-SPONGE:
B. Braun Surgical, S.A.  |  Carretera de Terrassa, 121  |  08191 Rubi  |  Spain

Vacuum source manufactured by:
MTG Medizinische-Technische Gerätebau GmbH  |  Zur Seilscheibe 10, 66280 Sulzbach/Saar  |  Germany

The main product trademark “AESCULAP” and the product trademarks “Endo-SPONGE” and “Eso-SPONGE” are registered trademarks of Aesculap AG.

Subject to technical changes. All rights reserved. This brochure may only be used for the exclusive purpose of obtaining information about our products. Reproduction in any form partial or otherwise is not permitted.